

# Seth E Karol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1491869/publications.pdf>

Version: 2024-02-01

71  
papers

1,264  
citations

471061

17  
h-index

414034

32  
g-index

71  
all docs

71  
docs citations

71  
times ranked

2084  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	1.7	5
2	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 845540.	1.3	10
3	Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29490.	0.8	1
4	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	2.5	20
5	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice. <i>Haematologica</i> , 2021, 106, 2095-2101.	1.7	6
6	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	0.6	3
7	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28730.	0.8	7
8	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
9	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	2.3	7
10	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease-Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	2.6	71
11	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 655-664.	1.1	5
12	Epidural blood patch for post-dural puncture headaches in adult and paediatric patients with malignancies: a review. <i>British Journal of Anaesthesia</i> , 2021, 126, 1200-1207.	1.5	5
13	Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29183.	0.8	6
14	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 622-637.	5.5	29
15	Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. <i>Cancer</i> , 2020, 126, 870-878.	2.0	17
16	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	0.8	38
17	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2020, 9, 6550-6555.	1.3	7
18	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. <i>Blood</i> , 2020, 136, 2955-2958.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	2.0	12
20	Team approach: Management of osteonecrosis in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28509.	0.8	6
21	Predicting success of desensitization after pegaspargase allergy. <i>Blood</i> , 2020, 135, 71-75.	0.6	20
22	Whole-body joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28336.	0.8	6
23	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092757.	1.1	13
24	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	5.1	92
25	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 329-344.	5.7	44
26	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e177-e181.	1.2	9
27	HLA Haplotype DRB1*07:01-DQA1*02:01-DQB1*02:02 Predicts Pegaspargase Hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB98.	1.5	0
28	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28244.	0.8	5
29	Pharmacogenomics and ALL treatment: How to optimize therapy. <i>Seminars in Hematology</i> , 2020, 57, 130-136.	1.8	9
30	Long-Term Functional Outcomes Among Childhood Survivors of Cancer Who Have a History of Osteonecrosis. <i>Physical Therapy</i> , 2020, 100, 509-522.	1.1	13
31	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
32	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. <i>Blood</i> , 2020, 136, 23-24.	0.6	3
33	Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles. <i>Blood</i> , 2020, 136, 30-31.	0.6	4
34	Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. <i>Blood</i> , 2020, 136, 11-12.	0.6	0
35	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. <i>Blood</i> , 2020, 136, 37-38.	0.6	8
36	A quality improvement project to improve pediatric medical provider sleep and communication during night shifts. <i>International Journal for Quality in Health Care</i> , 2019, 31, 633-638.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 983-986.	0.6	12
38	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019, 37, 2051-2061.	0.8	61
39	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019, 14, e0216328.	1.1	7
40	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	0.8	8
41	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27669.	0.8	11
42	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019, 134, 2649-2649.	0.6	12
43	Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10004-10004.	0.8	3
44	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	0.6	0
45	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018, 132, 2697-2697.	0.6	2
46	Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy. <i>Blood</i> , 2018, 132, 4029-4029.	0.6	0
47	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2665-2665.	0.6	0
48	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1325-1332.	3.3	25
49	Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26407.	0.8	1
50	Genome-Wide Study Links <i>PNPLA3</i> Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 131-140.	2.3	50
51	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i> , 2017, 123, 3602-3608.	2.0	11
52	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	0.7	17
53	Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 373-381.	2.3	40
54	Comparison of genome sequencing and clinical genotyping for pharmacogenes. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 380-388.	2.3	46

#	ARTICLE	IF	CITATIONS
55	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	0.6	56
56	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S177.	0.2	0
57	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	0.6	102
58	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	0.6	64
59	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 541-551.	1.3	16
60	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015, 47, 607-614.	9.4	126
61	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	1.2	31
62	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015, 126, 3714-3714.	0.6	2
63	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0135134.	1.1	13
64	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 250-250.	0.6	0
65	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 2295-2295.	0.6	0
66	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	0.6	6
67	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 3722-3722.	0.6	0
68	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. <i>Blood</i> , 2013, 122, 490-490.	0.6	0
69	Linkage analysis of neointimal hyperplasia and vascular wall transformation after balloon angioplasty. <i>Physiological Genomics</i> , 2006, 25, 286-293.	1.0	10
70	Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. <i>Blood</i> , 2006, 108, 2463-2469.	0.6	26
71	Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase. <i>Cancer Medicine</i> , 0, , .	1.3	0